AXGN:NSD-AxoGen Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 13.75

Change

+0.13 (+0.95)%

Market Cap

USD 0.56B

Volume

0.18M

Avg Analyst Target

USD 25.50 (+85.45%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

+5.52 (+0.94%)

USD46.66B 67.21 49.74
PODD Insulet Corporation

-8.58 (-2.86%)

USD20.70B 2,208.27 247.98
ABMD Abiomed Inc

-0.31 (-0.09%)

USD15.95B 103.89 50.66
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.28 (+0.36%)

USD11.66B 49.76 25.84
TNDM Tandem Diabetes Care Inc

-2.59 (-2.07%)

USD7.90B 1,216.99 251.84
SWAV ShockWave Medical Inc

+5.09 (+2.63%)

USD6.80B N/A N/A
INMD InMode Ltd

+1.65 (+1.98%)

USD6.37B 55.77 39.02
IART Integra LifeSciences Holdings ..

-0.02 (-0.03%)

USD5.72B 28.04 18.47
LIVN LivaNova PLC

-1.52 (-1.81%)

USD4.46B 77.40 N/A

ETFs Containing AXGN

Symbol Name Weight Mer Price(Change) Market Cap
HTEC Robo Global Healthcare Te.. 0.00 % 0.68 %

-0.22 (-0.48%)

USD0.24B
XMLH:XETRA Legal & General Ucits Etf.. 0.00 % 0.49 %

-0.22 (-1.38%)

USD0.22B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.18% 22% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.18% 22% F 20% F
Trailing 12 Months  
Capital Gain 2.31% 35% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.31% 35% F 29% F
Trailing 5 Years  
Capital Gain 54.49% 64% D 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.49% 64% D 52% F
Average Annual (5 Year Horizon)  
Capital Gain 44.67% 72% C- 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.67% 72% C- 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 102.64% 31% F 16% F
Risk Adjusted Return 43.52% 58% F 60% D-
Market Capitalization 0.56B 63% D 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.95 44% F 29% F
Price / Cash Flow Ratio -58.57 90% A- 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -18.49% 57% F 40% F
Return on Invested Capital -14.84% 59% F 31% F
Return on Assets -6.50% 64% D 32% F
Debt to Equity Ratio 42.96% 50% F 42% F
Technical Ratios  
Short Ratio 7.83 21% F 15% F
Short Percent 2.76% 64% D 51% F
Beta 0.75 71% C- 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector